## Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

MARRONE BIO INNOVATION Form 4 April 06, 2016	S INC				
FORM 4 LINITED STA	КЛ Л		OMB APPROVAL		
Washington, D.C. 20549		COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16.	T OF CHANGES IN BENEFICIAL OW SECURITIES	CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES		Expires: January 31 2005 Estimated average burden hours per	
may continue Section 17(a) of	t to Section 16(a) of the Securities Exchan The Public Utility Holding Company Act of 30(h) of the Investment Company Act of 19	of 1935 or Section	response	•	
(Print or Type Responses)					
1. Name and Address of Reporting Perso Vasavada Amit	<ul> <li><sup>n</sup> 2. Issuer Name and Ticker or Trading Symbol</li> <li>MARRONE BIO INNOVATIONS INC [MBII]</li> </ul>	5. Relationship of I Issuer (Check	Reporting Pers		
(Last) (First) (Middl C/O MARRONE BIO INNOVATIONS, INC., 1540 DF AVENUE	(Month/Day/Year) 04/04/2016	Director X Officer (give to below) VP Researc		o Owner er (specify pment	
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
DAVIS, CA 95618		Person		1 8	
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac	equired, Disposed of,	or Beneficial	ly Owned	
(Instr. 3) any	cution Date, if TransactionAcquired (A) or Code Disposed of (D) nth/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)	SecuritiesForBeneficially(DOwned(I)	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line for e	ach class of securities beneficially owned directly or	indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## 1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 2 4. 7. Title and Amount of 8 Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Γ Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4) S Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) ( Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Code V (A) (D) Date Expiration Title Amount Exercisable Date or Number of Shares Stock Option Common \$ 0.9331 04/04/2016 20,000 (1) 04/04/2026 20,000 Α Stock (Right to Buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** Other Director 10% Owner Officer Vasavada Amit C/O MARRONE BIO INNOVATIONS, INC. VP Research and Development 1540 DREW AVENUE **DAVIS, CA 95618** Signatures /s/ Linda V. Moore, as attorney-in-fact for Amit 04/06/2016 Vasavada \*\*Signature of Reporting Person Date **Explanation of Responses:** If the form is filed by more than one reporting person, see Instruction 4(b)(v).

## Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests with respect to 1/4 of the total shares subject to the option on the first anniversary of the vesting commencement date of April 4, 2016, and with respect to 1/48 of the total shares subject to the option monthly thereafter for 36 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.